The first clinically successful HDAC inhibitor is vorinostat, which is an orally active inhibitor with hydroxamic acid used to treat cutaneous T-cell lymphoma (CTCL). The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.